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Abstract: The objective of this study was to identify a panel of microRNAs (miRNAs) differentially
expressed in high-grade non-muscle invasive (NMI; TaG3–T1G3) urothelial carcinoma that progress
to muscle-invasive disease compared to those that remain non-muscle invasive, whether recurrence
happens or not. Eighty-nine high-grade NMI urothelial carcinoma lesions were identified and
total RNA was extracted from paraffin-embedded tissue. Patients were categorized as either
having a non-muscle invasive lesion with no evidence of progression over a 3-year period or as
having a similar lesion showing progression to muscle invasion over the same period. In addition,
comparison of miRNA expression levels between patients with and without prior intravesical therapy
was performed. Total RNA was pooled for microarray analysis in each group (non-progressors
and progressors), and qRT-PCR of individual samples validated differential expression between
non-progressive and progressive lesions. MiR-32-5p, -224-5p, and -412-3p were associated with
cancer-specific survival. Downregulation of miR-203a-3p and miR-205-5p were significantly linked
to progression in non-muscle invasive bladder tumors. These miRNAs include those implicated
in epithelial mesenchymal transition, previously identified as members of a panel characterizing
transition from the non-invasive to invasive phenotype in bladder tumors. Furthermore, we were
able to identify specific miRNAs that are linked to postoperative outcome in patients with high grade
NMI urothelial carcinoma of the bladder (UCB) that progressed to muscle-invasive (MI) disease.
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1. Introduction
Urothelial carcinoma of the bladder (UCB) is the fifth most commonly diagnosed cancer in the
United States, with a predicted incidence of 76,960 new cases and an estimated mortality of 16,390
individuals in 2016 [1]. Transitional cell carcinoma (TCC) is the most common form of UCB and can be
divided into two groups defined by distinct behaviors and different molecular profiles [2,3]. The first
group encompasses low-grade tumors which are always papillary and usually non-invasive (Ta) while
the second group consists of high-grade tumors, which can be either papillary or non-papillary and
are often invasive, either into the lamina propria (T1) or muscularis propria (T2). Non-muscle invasive
(NMI) tumors account for 75%–80% of bladder neoplasms, while the remaining 20%–25% are already
invasive or metastatic at the time of presentation [3].
NMI (Ta, T1 and in situ) tumors can be effectively treated via transurethral resection and
intravesical agents, although recurrence is common [2]. Between 50% and 70% of patients affected
with NMI tumors will have one or more recurrences after initial treatment, and about 10%–30% of
those patients will progress, presenting at a later date with a more aggressive lesion [3]. Multiple
recurrences, multiple lesions (>3), size of the tumor (>3 cm), T1 or high grade disease and the presence
of in situ carcinoma are risk factors for either recurrence or progression [3,4]. Therefore, patients at
risk for recurrence and/or progression undergo regular surveillance by cystoscopy and urine cytology.
A systematic review analyzing a total of 19 trials and over 3000 high-risk NMI patients showed that
events related to progression occur early and survival is poor in this specific group [5]. Given that 50%
of bladder cancers on average are fatal once they become muscle-invasive [2], the recent American
Urologic Association guidelines recommend radical cystectomy to be performed for high-risk NMI
disease, looking for a survival benefit, despite the morbidity associated with the surgery [6].
The goal of bladder cancer screening is to improve outcomes by facilitating the detection and
treatment of early-stage tumors which are destined to become muscle-invasive cancers. At this moment,
there is no clinical or laboratory marker that can definitively predict which patients will eventually
progress to muscle-invasive (MI) disease. A molecular marker with this ability could indicate the need
for radical treatment such as cystectomy to be performed months or even years before progression
providing an enormous survival benefit. On the other hand, patients with high-grade disease and
no risk of progression would be spared of the morbidity and mortality of the surgery as well as
preservation of their native bladders.
In addition, there has been consideration of the reclassification of T1 lesions with respect to the
depth of invasion characterized as in the subepithelial connective tissue or adjacent to the muscle,
once again indicative of different invasive potential [7,8]. Grade has also been shown to impact
progression-free survival [9]. Although early cystectomy is an option in patients with high grade
Ta or T1 bladder tumors the standard treatment of these tumors is transurethral resection (TURBT)
followed by intravesical therapy, typically with Bacille-Calmette-Guerin (BCG). The patient is then
followed through long-term cystoscopic surveillance with a repeat biopsy where disease progression
can be assessed [6]. It is reported that up to 25% of patients with high-grade Ta lesions will progress
to muscle-invasive disease [10,11], and under-staging of T1 lesions is reported to occur in ~20% of
patients who undergo TURBT restaging [12,13]. It is clear that these patients pose a significant clinical
challenge for the practicing urologist and that there is a need for new biomarkers that can more
accurately predict tumor behavior.
There have been numerous reports of genome-wide gene expression profiling of different bladder
tumor groups highlighting the expression of clusters of genes indicative of specific tumor type [14–21],
tumor behavior [22–25] or response to chemotherapeutic agents [26,27]. A similar approach has been
taken with microRNA (miRNA) profiling where altered expression of specific miRNAs has been
linked to bladder tumorigenesis [14,28–32] including predictors of outcome [33–36] and progression
to muscle-invasive (MI) disease [37]. Our group has previously reported a miRNA expression ratio
defining the invasive phenotype in bladder tumors [38] and identified an extended panel of miRNAs
involved in the transition from a non-invasive to an invasive bladder lesion [39] where many of the
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miRNAs identified in this new panel have been shown to be involved in the epithelial-mesenchymal
transition (EMT), a complex process involved in cancer progression [40–44]. In this study, we sought to
identify a miRNA panel that can prognosticate the invasive potential of high grade Ta and T1 lesions,
help better understand the mechanisms of this disease, and ultimately serve to guide the clinician in
deciding upon the appropriate path for patient management. In addition, miRNA expression was
examined in a cohort of patients with prior intravesical therapy in an effort to better understand the
molecular mechanisms involved.
2. Materials and Methods
2.1. Patient Tissue Samples
We have collected tissue samples under IRB-approved protocols from Lahey Hospital and Medical
Center or University of Wisconsin patients diagnosed with urothelial carcinoma of the bladder between
1989 and 2008. Criteria for inclusion were a histologic diagnosis of TaG3 or T1G3 with sufficient
tissue material for analysis. The T1G3 tumors were re-resected (re-TURBT) as standard-of-care for
accuracy/restaging to confirm absence of muscle invasion, as clinically indicated. Formalin-fixed,
paraffin-embedded tumor tissue from patients was retrieved from the archives of the Pathology
Department. Patient charts were reviewed for relevant clinical data, including prior history of
intravesical therapy, concomitant histologic features and determination of final clinical stage at the
most recent follow-up. Exclusion criteria included previous tumors of the upper urinary tract, prior
intravesical therapy or systemic chemotherapy, metasynchronous lesions (e.g., carcinoma in situ
(CIS) or squamous or adenocarcinoma), previous radiation to the pelvis (including brachytherapy)
or less than three years of follow-up for non-progressive tumors. These criteria were placed on
samples submitted for microarray analysis and validation by qRT-PCR. Patients with CIS (previous
or concomitant) or previous intravesical therapy were included in an expanded sample set to further
elucidate differential miRNA expression in progressors vs. non-progressors, using qRT-PCR analysis.
Progression was defined as muscle invasion (stage T2 or higher) or metastatic disease and was
determined by review of the clinical records. Tumor stage was determined using tumor metastasis
nodes (TMN) classification and graded according to the WHO guidelines. Five micron sections from
tissue samples were cut and stained with hematoxylin and eosin for the assessment of tumor content.
Only samples with >60% tumor content were included in this study.
2.2. RNA Extraction
Total RNA was extracted from sequential formalin fixed paraffin embedded (FFPE) sections
using the RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion, Houston, TX, USA) according
to manufacturer’s protocol. Total RNA was quantified using Quant-IT RNA Assay Kit (Invitrogen,
Carlsbad, CA, USA) detected with the Qubit-fluorometer (Invitrogen).
2.3. Microarray Analysis
Total RNA from patients was pooled into two groups: (1) TaG3 or T1G3 without clinical
progression and (2) TaG3 or T1G3 with progression to ≥T2 disease. An equal quantity of total
RNA was used for each pool (11 µg), and each member within a pool contributed an equal quantity
of RNA. The RNA was analyzed using miRCURY™ LNA Array microRNA Profiling. Briefly, after
quality control was performed to determine RNA integrity, concentration, and content of small RNA,
RNA was labeled with Hy3™ and Hy5™ fluorophores using the miRCURY™ LNA Array Power
labeling kit (Exiqon, Vedbaek, Denmark) and hybridized to the miRCURY™ LNA Array (Exiqon).
Dye swap was performed to ensure data was not dependent on labeling technique.
Data was obtained as a median of replicated fluorescent signal measurements of the same miRNA
from each slide for 1266 miRNAs. Slides were analyzed using Exiqon’s protocol. In addition to the
raw data for each data point, an expression matrix was performed containing the normalized log2
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transformed Hy3/Hy5 ratios. Normalization included background subtractions with a global Lowess
(LOcally WEighted Scatterpoint Smoothing) regression algorithm. Spots were flagged and analyzed
for signal quality (empty spot, spot signal less than background, less than optimal spot morphology or
saturated spot). Flagged miRNAs were excluded from Exiqon’s analysis. Dye-swap was performed to
mitigate labeling bias.
2.4. Quantitative Real Time RT-PCR
qRT-PCR quantification of mature miRNAs was conducted using TaqMan miRNA quantification
kits following the manufacturer’s protocol (Applied Biosystems, Foster City, CA, USA). Briefly, 5 ng of
total RNA was used for reverse transcription and 0.33 ng of cDNA was used per reaction in real-time
PCR analysis. Each qRT-PCR reaction was performed in triplicate. MiRNAs for this analysis were
based on the differential expression found in the microarray and previous work by our group predictive
of urothelial cancer invasiveness [39]. Normalization of miRNA expression was performed using
miR-222-3p as previously described [39], and relative expression levels were calculated using the
2−∆Ct method.
2.5. Statistical Analysis
To determine whether the miRNAs reported in this study were predictive of progression to
invasive disease we used logistic regression with the progressive status being a response and the
log-transformed miRNA measurement as a predictor. For univariate overall and cancer-specific
survival analysis we used the product-limit procedure (Kaplan-Meier method), with the surgery as the
entry date and the continuous miRNA variables were dichotomized (e.g., low vs. high expression)
based on the median level of expression. The log-rank (Cox-Mantel) test was used to compare the
survival curves for each variable.
To determine the prognostic value of each miRNA in terms of disease-free and overall survival
among Ta/T1G3 bladder cancer patients, we used Cox proportional hazard regression to calculate the
hazard ratios (HR) for each model. Other prognostic factors, such as age, therapy, and CIS status were
tested in univariate proportional hazards Cox models. However, no significant effect on the hazard of
cancer progression was observed; therefore, they were not included in the final models.
Comparison of miRNA expression levels between all patients (progressors plus non-progressors)
with and without prior intravesical therapy as well as comparison of miRNA expression levels and
survival status were performed using a t-test or ANOVA with Games-Howell post-hoc analysis,
as appropriate. Normality assumption was tested using the Shapiro-Wilks test; in those cases
where normality assumption was violated, Wilcoxon-Mann-Whitney non-parametric test was used.
A p-value < 0.050 was considered significant.
3. Results
3.1. Discovery Sample Set
Microarray analysis and initial qRT-PCR validation was performed with two groups of samples,
a total of 17 patients, including both non-progressors and progressors. The non-progressors (10 patients)
presented with Ta/T1G3 tumors and displayed no evidence of progression to muscle-invasive disease
in a three-year follow-up period. The progressors (7 patients) presented with Ta/T1 tumors and
displayed progression to muscle-invasive cancer within three years. Table 1A details the two groups
and clinical profile of these patients. There was a higher percentage of males in the progressor group.
For microarray analysis RNA was pooled for each group, and validation of differentially expressed
miRNAs, via qRT-PCR, was performed on individual samples. None of the 17 patients were treated
with prior intravesical therapy nor was there evidence that they had CIS prior to, or concurrently,
with the tumor analyzed in this study.
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Table 1. Clinical profile of patients. 1A: discovery sample set used in the microarray analysis and the
initial qRT-PCR validation. 1B: expanded sample set of patients used in qRT-PCR analysis. mo = months;
SD = standard deviation; UW = University of Wisconsin.
Table 1A: Discovery Sample Set Non-Progressor Progressor
n 10 7
TaG3/T1G3 (n/n) 5/5 4/3
Male (%) 70 86
Age (mean years ± SD) 71 ± 8 73 ± 7
Time to progression (mean mo ± SD) n/a 34 ± 37
Time to follow-up (mean mo ± SD) 88 ± 29 55 ± 43
Table 1B: Expanded Sample Set Non-Progressor Progressor
n 67 22
TaG3/T1G3 (n/n) 37/30 7/15
Male (%) 78 86
Age (mean yrs ± SD) 69 ± 9 73 ± 7
Time to progression (mean mo ± SD) n/a 25 ± 26
Time to follow-up (mean mo ± SD) 73 ± 32 49 ± 33
Intravesical therapy (n, %) 11, 16% 5, 23%
Status (alive, %) 49, 73% 10, 45%
Site (Lahey/UW) 53/14 18/4
3.2. Microarray Results for miRNAs Differentially Expressed in Non-Progressive Versus Progressive
High-Grade Ta and T1 Lesions: Discovery Sample Set
To study changes in expression levels of miRNAs that might be relevant to progression of UCB,
we performed miRNA microarray analysis on high-grade, NMI UCBs that did not progress over a
three-year follow up period (Ta–T1) and those that progressed from the NMI state to muscle-invasive
(≥T2). Analysis of microarray data from both non-progressive and progressive TaG3 and T1G3 lesions
was performed by identification of miRNA showing >1.5 or <−1.5-fold change in expression between
groups. Using this criterion, we identified 19 miRNAs displaying differential expression between
non-progressive and progressive tumor groups (Table 2).
Table 2. Discovery sample set: MicroRNAs (miRNAs) differentially expressed between the
non-progressor and progressor groups. Negative fold change values indicate expression was higher in
non-progressors. Microarray results of the fold change in expression are based on comparing pooled
samples from each group. The qRT-PCR results (fold change, means, std. dev., and p-value) reflect an
analysis of individual samples for each group (non-progresor group n = 10 and progressor group n = 7).








Mean Std. Dev. Mean Std. Dev.
hsa-miR-125b-5p 2.46 3.28 0.057 0.64 1.10 2.09 1.54
hsa-miR-145-5p 2.09 3.51 0.031 0.10 0.10 0.37 0.25
hsa-miR-223-3p 1.82 4.32 0.102 0.26 0.23 1.11 1.16
hsa-miR-143-3p 1.70 1.96 0.103 0.15 0.20 0.30 0.15
hsa-miR-338-5p 1.69 2.96 0.274 0.00 0.00 0.01 0.02
hsa-miR-31-5p −2.71 −2.24 0.143 5.24 5.29 2.34 2.10
hsa-miR-203a-3p −2.59 −4.75 0.025 0.54 0.49 0.11 0.13
hsa-miR-141-3p −2.44 −3.04 0.008 2.18 1.25 0.72 0.71
hsa-miR-200a-3p −2.25 −2.19 0.021 5.12 2.85 2.34 1.56
hsa-miR-205-5p −2.12 −3.05 0.034 15.97 12.90 5.24 5.06
hsa-miR-429 −2.09 −1.55 0.366 0.63 0.62 0.41 0.36
hsa-miR-29c-3p −1.92 −1.61 0.339 1.02 1.08 0.63 0.50
hsa-miR-20a-5p −1.88 −1.43 0.299 1.79 1.15 1.25 0.91
hsa-miR-29b-3p −1.86 −1.87 0.064 0.36 0.23 0.19 0.10
hsa-miR-19b-3p −1.77 −2.13 0.080 1.73 1.36 0.81 0.59
hsa-miR-17-5p −1.72 −1.29 0.443 1.87 1.12 1.45 1.04
hsa-miR-106a-5p −1.71 −1.29 0.446 1.67 0.99 1.30 0.97
hsa-miR-200b-3p −1.63 −1.34 0.335 4.98 2.29 3.70 2.76
hsa-miR-30e-5p −1.58 −1.23 0.547 0.88 0.77 0.72 0.29
Genes 2017, 8, 77 6 of 15
3.3. Validation of Differential Expression of miRNAs Using qRT-PCR: Discovery Sample Set
Validation of differential expression was performed using qRT-PCR of individual samples, initially
on the 17 samples used in microarray analysis. Differentially expressed miRNAs were chosen for
further analysis based on the microarray results and comprised 5 of the upregulated and 14 of the
downregulated miRNAs identified in the microarray. For each of the nineteen miRNAs analyzed the
qRT-PCR levels obtained were of a similar level of magnitude between the groups corresponding to the
results obtained in microarray analysis (Table 2). The differences observed were statistically significant
for five out of the nineteen miRNAs where miR-145-5p was the only significantly up-regulated miRNA
while miR-141-3p, -200a-3p, -203a-3p, and miR-205-5p were significantly down-regulated in the
progressor group.
3.4. miRNA Expression of an Expanded Sample Set Including Patients with CIS and/or Therapy
In order to investigate miRNA expression using a larger sample size and more clinically complex
samples, qRT-PCR was performed on an expanded group of 89 Ta–T1/G3 human tumor samples
(Table 1B) consisting of 67 non-progressors and 22 progressors inclusive of the 17 samples from the
discovery set. Compared to the discovery set, the percentage of males was better balanced between
the non-progressor and progressor goups in this expanded set. We also expanded the total number
of miRNAs analyzed to 35 (Supplemental Materials Table S1) based on the differential expression
found in the microarray and previous work by our group. The original samples used in miRNA
microarrays were selected to be as homogeneous as we could obtain i.e., presenting with Ta–T1/G3
lesions alone, while the additional samples analyzed were chosen to have confounding factors that
mirror the clinical presentations seen in the majority of patients presenting with high grade Ta/T1
disease. These additional factors included prior therapy and/or CIS. Analysis of the qRT-PCR results
revealed that one of the progressor patients was an outlier as their expression levels were, on average,
15-fold higher compared to the other samples in the progressor group. Removal of this sample from
the analysis revealed a statistically significant difference between non-progressive and progressive
samples for 18 miRNAs (Figure 1).
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Although the additional patients helped to increase the power of the study, they also had
confounding factors such as prior intravesical treatment; hence we considered the effect of therapy on
miRNA expression. Comparison of miRNA expression levels between patients with and without prior
intravesical therapy showed five of the miRNAs tested were significantly different between the two
groups. When this analysis was restricted to the progressor-only group, six miRNAs were significant.
When restricted to the non-progressor group, there were 19 miRNAs displaying significant expression
profile change in the different therapy groups (Table 3). Expression of the miRNA-15a-5p and -200a-3p
were significantly decreased in all patients receiving therapy, even when investigating progressors and
non-progressors separately.
Table 3. Relative expression of miRNAs differentially expressed between patients of the expanded
sample set with or without intravesical therapy. Negative fold change values indicate expression was
higher in patients without therapy. Mean values are expressed as 2−∆Ct. std. dev. = standard deviation.
All Patients of the Expanded Sample Set (n = 88) Without Therapy With Therapy
miRNA fold change p-value mean std. dev. mean std. dev.
hsa-miR-15a-5p −3.00 <0.001 0.37 0.32 0.12 0.05
hsa-miR-20a-5p −2.71 <0.001 1.40 1.38 0.52 0.29
hsa-miR-21-5p −2.24 0.003 8.83 10.31 3.93 3.86
hsa-miR-200a-3p −3.58 <0.001 3.65 5.25 1.02 1.06
hsa-miR-1308 −2.79 <0.001 171.92 191.95 61.63 42.86
Within Progressors Only (n = 21) Without Therapy With Therapy
miRNA fold change p-value mean std. dev. mean std. dev.
hsa-miR-15a-5p −2.32 0.004 0.33 0.15 0.14 0.06
hsa-miR-32-5p −3.13 0.010 0.01 0.01 0.00 0.00
hsa-miR-141-3p −3.02 0.011 0.88 0.77 0.29 0.19
hsa-miR-200a-3p −2.31 0.011 2.11 1.37 0.91 0.48
hsa-miR-200c-3p −2.05 0.014 10.51 6.26 5.12 2.33
hsa-miR-429 −2.17 0.034 0.32 0.28 0.15 0.07
Within Non-Progressors Only (n = 67) Without Therapy With Therapy
miRNA fold change p-value mean std. dev. mean std. dev.
hsa-miR-15a-5p −3.33 <0.001 0.38 0.36 0.11 0.05
hsa-miR-17-5p −2.56 <0.001 1.82 1.62 0.71 0.46
hsa-miR-19a-3p −2.93 <0.001 0.24 0.26 0.08 0.06
hsa-miR-19b-3p −2.20 0.004 1.58 1.73 0.72 0.57
hsa-miR-20a-5p −2.99 <0.001 1.55 1.48 0.52 0.33
hsa-miR-21-5p −3.21 <0.001 9.87 11.36 3.08 3.52
hsa-miR-29b-3p −2.37 0.008 0.42 0.63 0.18 0.09
hsa-miR-30b-5p −1.64 0.012 3.10 3.07 1.89 0.75
hsa-miR-30e-5p −1.90 0.005 1.36 1.31 0.71 0.28
hsa-miR-32-5p −2.23 0.018 0.01 0.02 0.01 0.00
hsa-miR-106a-5p −2.27 0.002 1.66 1.51 0.73 0.52
hsa-miR-135a-5p −6.99 0.003 0.08 0.14 0.01 0.01
hsa-miR-141-3p −2.42 0.005 1.41 1.48 0.59 0.64
hsa-miR-200a-3p −3.90 <0.001 4.11 5.88 1.06 1.23
hsa-miR-200b-3p −2.27 0.003 4.68 4.24 2.07 1.95
hsa-miR-203a-3p −2.99 0.010 0.93 1.58 0.31 0.32
hsa-miR-301a-3p −5.56 0.012 0.09 0.20 0.02 0.01
hsa-miR-429 −3.72 0.002 0.56 0.86 0.15 0.18
hsa-miR-1308 −2.81 0.001 177.74 208.59 63.22 37.36
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3.5. miRNAs Indicative of Progression
Logistic regression was used to investigate the predictive ability of miRNA expression levels on
the cancer progression status. When the logistic regression model fit the data with miRNA expression
only, miR-203a-3p (p = 0.054) and miR-205-5p (p = 0.080) trended towards significance but none of the
miRNAs had a statistically significant effect (p-values < 0.050) in predicting the progression status.
Since several of the miRNA expression levels were significantly altered within treatment groups,
we included two additional logistic regression models when analyzing the predictive status of the
miRNAs. One model included miRNA expression levels and therapy status while the second
model incorporated miRNA expression levels, therapy status and their interaction. Although
miR-203a-3p (p = 0.054) and miR-205-5p (p = 0.068) trended toward significance, none of the miRNAs
showed a statistically significant effect in predicting progression when miRNA expression levels were
combined with treatment. The second model, which involved combining the therapy status of each
group and their interaction, revealed miR-30b-5p with significant effect in predicting progression
(p = 0.044) and miR-203a-3p (p = 0.054), miR-20a-5p (p = 0.054) and miR-205-5p (p = 0.065) all trending
toward significance.
As expression levels of miR-203a-3p and miR-205-5p appeared to be reduced in the group that
progressed to invasive disease, we analyzed whether the expression levels of these two miRNAs
were reduced in invasive tumors when compared to non-muscle invasive tumors. For this analysis
we examined 26 cases representing TaG1 and 31 cases of muscle invasive (≥T2) UCB (Supplemental
Materials Table S2), in addition to the expanded sample set. Results of this comparison revealed
a decrease in the expression levels of miR-203a-3p and miR-205-5p correlated with the degree of
invasiveness of the tumor samples (Figure 2) whereby TaG1 lesions expressed the highest levels of
miR-203a-3p and miR-205-5p over the ≥T2 invasive lesions.
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Figure 2. Normalized qRT-PCR expression levels. Expression correlated with the degree of invasiveness
of the tumor samples for (A) miR-203a-3p and (B) miR-205-5p. Error bars represent the standard error
of the mean. Significant differences are indicated with brackets; all remaining comparisons were not
significant at p < 0.050.
3.6. miRNAs Indicative of Mortality
Logistic regression was used to investigate the predictive ability of all miRNA expression levels
tested for cancer specific and overall mortality. When the logistic regression model fit the data
with miRNA expression only, miR-412-3p was significant in predicting overall mortality (p = 0.020),
and miR-412-3p and miR-32-5p were significant in predicting cancer specific mortality (p = 0.037 and
p = 0.049 respectively).
3.7. Time to Progression Analyses
The Cox proportional hazards model was used to investigate whether or not a significant change
in specific miRNA expression levels corresponded with time to progress to muscle invasive disease.
Multivariate ox re r ssi l sis f i s sho ed two miRNAs, miR-205-5p and miR-203a-3p
that wer significantly associated with time to progression ( i - - : r ratio (HR), 0.789;
p = 0.014; miR-203: HR, 0.854; p = 0.027). Both of these miRNAs were found to be downregulated
in the progressor group and for each two-fold increase in the miRNA levels, instantaneous risk of
progression decreases by 21 and 15 for i -205-5 a i -203a-3 , r s cti l .
Kaplan-Meier analysis of time to progression revealed that higher levels of miR-205-5p were
associated with a higher probability of non-progression (p = 0.013, Figure 3). The median time
to progression in the group with low xpression of miR-205-5p was 113 months compared to t e
high expression group where this time was not reached. I addition, higher levels of miR-17-5p
and miR-20a-5p were lso associ ted with a higher probability of non-progression (p = 0.048 and
p = 0.031, respectively).
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absence of additional clinical changes e.g., carcinoma in situ. Extension of this tumor group to further
validate findings from the microarray profiles included NMI lesions with concurrent CIS and/or
prior intravesical treatment. Such samples were included because of the lack of numbers of patients
exhibiting non-invasive lesions alone. Such samples sully the analysis and at the same time expand
consideration of the role of different clinical parameters on miRNA expression influencing the behavior
of tumors emanating from the NMI group.
When using a 1.5-fold cut-off, the microarray analysis revealed 19 miRNAs were differentially
expressed between the non-progressor and progressor groups, and five of these were significantly
differentially expressed based on qRT-PCR results of the discovery sample set. A more extensive
analysis of the expanded sample set for 35 miRNAs revealed that eighteen were significantly
down-regulated in the progressor group. Six of these were also identified previously by this
group as being down-regulated in muscle invasive as compared to non-muscle invasive disease [39].
Interestingly, many of these miRNAs have also been linked to the epithelial-mesenchymal transition
(EMT) [40–42] including miR-31-5p, -200a-3p, -200b-3p, -203a-3p and -205-5p. MiR-203a-3p is
implicated in keratinocyte differentiation [46] and the stem cell phenotype [47] including increased
expression of ABL-1 and BCR-ABL-1 [48] whilst miR-205-5p is considered part of the miR-200 family
linked to EMT [46], an event previously recorded in bladder tumorigenesis [38,39].
Several studies have implicated miRNAs as prognostic markers for UCB, and the study by
Rosenberg et al. [37] is of particular interest to the work presented here. Their study also identified
miRNAs associated with progression and survival in tumors from patients that initially presented
with non-invasive disease. Several of the miRNAs they identified with reduced expression between
progressors and non-progressors were also differentially expressed in this microarray analysis,
including miR-29c-3p, -31-5p, -141-3p, and -205-5p. The qRT-PCR analysis of our expanded sample
set similarly noted significantly decreased expression of these four miRNAs. Conversely, they found
increased expression for miR-17-5p, -19b-3p, -20a-5p, and -106a-5p. However, the present data reflect
a sample set restricted to only high grade samples, and included cases with CIS and/or intravesical
therapy. Furthermore, some of the discrepancies between our study and the Rosenberg study may be
accounted for by the differences in analytical platforms. Nonetheless, miR-205-5p stands out in both
studies as a marker of progressive UCB. Some of the known targets of miR-205-5p include ZEB1/2 [40],
PTEN [49], HER3 [50], SHIP2 [51], VEGFA [52] and E2F1, E2F5, and PKCε [53].
In the present study additional miRNAs have also been associated with progression as well
as survival. The miRs -17-5p, -20a-5p, -30b-5p and -203a-3p were associated with progression, and
miRs -19b-3p, -32-5p, -224-5p, and -412-3p were related to cancer-specific survival. Many of these
have been reported to play a role in carcinogenesis. Upregulation of the miR-17-5p cluster, which
includes miR-17-5p and -20a-5p, has been shown to inhibit progression of colorectal carcinoma [54].
This correlates with the higher levels of these miRNAs observed in this study for non-progressing
tumors. Likewise, suppression of tumorigenesis by miR-203a-3p and -205-5p has been identified in
numerous studies of cancer including UCB [55,56], and their use as clinical markers and in potential
treatment strategies needs to be championed.
Moreover, this study provided an elemental examination of miRNAs differentially expressed
between tumor specimens treated with or without intravesical therapy. This is of importance because
the mechanism of several miRNAs implicated in UCB has been reported, and in some cases their use
as potential therapies has been proposed. Of particular note, recently Inamoto et al [57] administered
miR-145-5p in an intravesical orthotopic mouse model, and observed a 76% decrease in tumor growth
along with increased survival. In the present study miR-145-5p was observed to be differentially
expressed in tumors of patients that received intravesical therapy, and others noted here likely warrant
similar investigation as therapeutic agents.
In this study we have shown the link of altered expression in different miRNAs indicative of
disease progression in non-muscle invasive bladder tumors providing tools for the urologist on which
to base clinical management decisions in this subgroup of patients. Secondarily, we have identified
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miRNA panels whose expression profile is affected in their therapeutic response. This provides a
platform for future studies to identify definitive miRNA profiles indicative of response to treatment,
and bolsters the evidence of a role for miRNA-based therapies in UCB. Further validation in a
multi-institutional study is warranted.
5. Conclusions
We have identified miRNAs associated with a progressive phenotype and survival in UCB, and
several of these miRNAs have been linked with EMT. Specifically, levels of miR-203a-3p and miR-205-5p
correlated with the degree of invasiveness of the tumor samples, and both miRNAs were significantly
associated with time to progression. Two miRNAs (miR-412-3p and miR-224-5p) were significantly
associated with time to death from UCB. In addition, a preliminary analysis comparing patients with
and without intravesical therapy revealed specific miRNAs differentially expressed between these
groups. These could serve as a basis for further research into potential therapeutic agents.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/8/2/77/s1, Table S1:
Relative expression within the expanded sample set for the 35 miRNA tested by qRT-PCR, Table S2: Clinical
profile of the additional patients analyzed for miR-203-3p and miR-205-5p and compared to the non-progressors
and progressors.
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